Simplify Logo

Full-Time

Senior Clinical Scientist

Confirmed live in the last 24 hours

Verve Therapeutics

Verve Therapeutics

201-500 employees

Developing gene editing therapies for heart disease

Hardware
Biotechnology
Healthcare

Senior

Boston, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Requirements
  • Advanced degree in life sciences (e.g. PhD, PharmD, MD, Masters etc.) with 5+ years of relevant experience including 3 years of clinical development experience
  • Familiarity with key clinical study documents
  • Experience with analysis and review of clinical data
  • Working knowledge of biostatistics, GCP, and regulatory requirements for clinical studies
  • Experience working with CROs and external vendors
  • Strong attention to detail and organizational skills
  • Exceptional verbal and written communication skills
  • Ability to build strong relationships and work effectively with cross-functional teams
Responsibilities
  • Partners with other clinical scientists and medical monitor on oversight of clinical trial activities, including safety reviews and site interactions
  • Organize and lead process for review of potential patients for study participation
  • Review, analyze, and interpret emerging clinical trial data
  • Liase with the broader clinical development team at Verve (clinical operations, data management, and regulatory teams)
  • Contribute to authoring key study and regulatory documents (e.g. protocol, ICF, study manuals)
  • Leads internal meetings to review topics and develop mitigation plans
  • Contribute to the development of presentations emerging from clinical studies
  • Ensure compliance of all activities with ICH/GCP guidelines, applicable regulatory requirements, and Verve SOPs
  • Other duties as assigned

Verve Therapeutics is developing single-course gene editing medicines to address cardiovascular disease, with a focus on precision genetic editing technologies to lower LDL cholesterol and triglyceride levels. Their lead program, VERVE-101, targets heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Company Stage

IPO

Total Funding

$419.3M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

7%

1 year growth

5%

2 year growth

54%